Benzinga | Aug 5, 2021 04:14PM EDT

Cytokinetics Q2 EPS $(0.86) Misses $(0.65) Estimate, Sales $2.84M Down From $3.59M YoY

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.65) by 32.31 percent. This is a 26.47 percent decrease over losses of $(0.68) per share from the same period last year. The company reported $2.84 million in sales this quarter. This is a 20.87 percent decrease over sales of $3.59 million the same period last year.